Title of article
Use of pentoxifylline in membranous nephropathy
Author/Authors
Didier Ducloux، نويسنده , , Catherine Bresson-Vautrin، نويسنده , , Jean-Marc Chalopin، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2001
Pages
2
From page
1672
To page
1673
Abstract
Urinary TNF-α excretion correlates with proteinuria in patients with membranous nephropathy (MGN). Pentoxifylline suppresses or reduces the production of TNF-α. Between April, 1999 and August, 2000, we did a single-centre, prospective, pilot study to assess the effects of pentoxifylline (1200 mg/day) on proteinuria in patients with idiopathic MGN. Ten patients were included and treated for 6 months. Pentoxifylline significantly decreased proteinuria from 11g/day [range 4·6–27] to 1·8 (0–10·9); p=0·001). Pentoxifylline may be a safe and effective adjunct to steroids and immunosuppressants in patients with MGN.
Journal title
The Lancet
Serial Year
2001
Journal title
The Lancet
Record number
565124
Link To Document